Skip to main content
OpenTrials
Completed

NCT Number: NCT03196297

A Trial Evaluating Efficacy and Safety of Prophylactic Administration of Concizumab in Patients With Severe Haemophilia A Without Inhibitors

This trial is conducted in Asia, Europe and the United States of America (USA). The aim of the trial is to assess the efficacy of concizumab administered s.c. (subcutaneously, under the skin) once daily in preventing bleeding episodes in patients with severe haemophilia A without inhibitors.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Haemostasis Blood Coagulation Disorders Blood Coagulation Disorders, Inherited Coagulation Protein Disorders Congenital, Hereditary, and Neonatal Diseases and Abnormalities Genetic Diseases, Inborn Haemophilia A Hematologic Diseases Hemic and Lymphatic Diseases Hemophilia A Hemorrhagic Disorders

Age range

18 year and older

Sex eligibility

Male

Study type

Interventional

Phase

Phase 2

Primary location

Novo Nordisk Investigational Site, Brest, France

Loading trial locations.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

- Informed consent obtained before any trial-related activities. Trial-related activities are any procedures that are carried out as part of the trial, including activities to determine the suitability for the trial - Male patients aged 18 years or older at the time of signing informed consent, diagnosed with severe haemophilia A (FVIII activity below 1%), based on medical records or results at screening Exclusion Criteria: - Known or suspected hypersensitivity to trial product(s) or related products - Known inherited or acquired bleeding disorder other than haemophilia A - Presence of inhibitors (neutralising antibodies) to Factor VIII (equal to or above 0.6 Bethesda Units) at screening measured by the Nijmegen method

Treatment and study plan

Concizumab

Drug

0.15 mg/kg (with potential stepwise dose administration to 0.25 mg/kg) administered daily s.c (subcutaneously, under the skin). Treatment duration is 24 weeks in the main phase, and 52 weeks in the extension phase

turoctocog alfa

Drug

Breakthrough bleeding episodes will be treated by the patients at home with turoctocog alfa at the discretion of the study doctor, who will also choose dose levels

Primary outcomes

  1. The Number of Bleeding Episodes During at Least 24 Weeks From Treatment Onset

    Time frame: During at least 24 weeks from treatment onset

    The number of bleeding episodes that were treated during at least 24 weeks from treatment onset are presented. The data is presented while on last dose level when the bleed occurred.

Secondary outcomes

  1. The Number of Bleeding Episodes During at Least 76 Weeks From Treatment Onset

    Time frame: During at least 76 weeks from treatment onset

    The number of bleeding episodes that were treated during at least 76 weeks from treatment onset are presented. The data is presented while on last dose level when the bleed occurred.

  2. The Number of Spontaneous Bleeding Episodes During at Least 24 Weeks From Treatment Onset

    Time frame: During at least 24 weeks from treatment onset

    Bleeds that were not linked to a specific, known action or event are called spontaneous bleeding episodes. The number of spontaneous bleeding episodes that were treated during at least 24 weeks from treatment onset are presented. The data is presented while on last dose level when the bleed occurred.

  3. The Number of Spontaneous Bleeding Episodes During at Least 76 Weeks From Treatment Onset

    Time frame: During at least 76 weeks from treatment onset

    Bleeds that were not linked to a specific, known action or event are called spontaneous bleeding episodes. The number of spontaneous bleeding episodes that were treated during at least 76 weeks from treatment onset are presented. The data is presented while on last dose level when the bleed occurred.

  4. Number of Treatment-emergent Adverse Events (TEAEs) During at Least 24 Weeks From Treatment Onset

    Time frame: During at least 24 weeks from treatment onset (week 0)

    An adverse event (AE) was any untoward medical occurrence in a participant administered a medicinal product, and which does not necessarily had a causal relationship with this treatment. A TEAE was defined as an event that had onset from the first exposure to treatment until the last visit in the trial. Number of TEAEs that occurred during at least 24 weeks from treatment onset (week 0) are presented. The data is presented per dose level participants were on at the time of onset of the adverse event.

  5. Number of Treatment-emergent Adverse Events (TEAEs) During at Least 76 Weeks From Treatment Onset

    Time frame: During at least 76 weeks from treatment onset (week 0)

    An adverse event (AE) was any untoward medical occurrence in a participant administered a medicinal product, and which does not necessarily had a causal relationship with this treatment. A TEAE was defined as an event that had onset from the first exposure to treatment until the last visit in the trial. Number of TEAEs that occurred during at least 76 weeks from treatment onset (week 0) are presented. The data is presented per dose level participants were on at the time of onset of the adverse event.

  6. Occurrence of Anti-concizumab Antibodies During at Least 24 Weeks From Treatment Onset

    Time frame: During at least 24 weeks from treatment onset (week 0)

    Occurrence of anti-concizumab antibodies during at least 24 weeks from treatment onset (week 0) is presented. In the reported data, 'Yes' infers number of participants who showed positive anti-concizumab antibody tests whereas 'No' infers number of participants who showed negative anti-concizumab antibody tests.

  7. Occurrence of Anti-concizumab Antibodies During at Least 76 Weeks From Treatment Onset

    Time frame: During at least 76 weeks from treatment onset (week 0)

    Occurrence of anti-concizumab antibodies during at least 76 weeks from treatment onset (week 0) is presented. In the reported data, 'Yes' infers number of participants who showed positive anti-concizumab antibody tests whereas 'No' infers number of participants who showed negative anti-concizumab antibody tests.

  8. Change in Fibrinogen During 24 Weeks From Treatment Onset

    Time frame: During 24 weeks from treatment onset (week 0)

    Change in fibrinogen during 24 weeks from treatment onset (week 0) is presented. The data is presented per the last dose level which the participants have reached at the time of assessment.

  9. Change in Fibrinogen During at Least 76 Weeks From Treatment Onset

    Time frame: During at least 76 weeks from treatment onset (week 0)

    Change in fibrinogen during at least 76 weeks from treatment onset (week 0) is presented. The data is presented per the last dose level which the participants have reached at the time of assessment.

  10. Change in D-dimer During 24 Weeks From Treatment Onset

    Time frame: During 24 weeks from treatment onset (week 0)

    Change in D-dimer during at least 24 weeks from treatment onset (week 0) is presented. The data is presented per the last dose level which the participants have reached at the time of assessment.

  11. Change in D-dimer During at Least 76 Weeks From Treatment Onset

    Time frame: During at least 76 weeks from treatment onset (week 0)

    Change in D-dimer during at least 76 weeks from treatment onset (week 0) is presented. The data is presented per the last dose level which the participants have reached at the time of assessment.

  12. Change in Prothrombin Fragment 1 + 2 (F1 + F2) During 24 Weeks From Treatment Onset

    Time frame: During 24 weeks from treatment onset (week 0)

    Change in F1 + F2 during 24 weeks from treatment onset (week 0) is presented. The data is presented per the last dose level which the participants have reached at the time of assessment.

  13. Change in Prothrombin Fragment 1 + 2 (F1 + F2) During at Least 76 Weeks From Treatment Onset

    Time frame: During at least 76 weeks from treatment onset (week 0)

    Change in F1 + F2 during at least 76 weeks from treatment onset (week 0) is presented. The data is presented per the last dose level which the participants have reached at the time of assessment.

  14. Change in Prothrombin Time (PT) During 24 Weeks From Treatment Onset

    Time frame: During 24 weeks from treatment onset (week 0)

    Change in PT during 24 weeks from treatment onset (week 0) is presented. The data is presented per the last dose level which the participants have reached at the time of assessment.

  15. Change in Prothrombin Time (PT) During at Least 76 Weeks From Treatment Onset

    Time frame: During at least 76 weeks from treatment onset (week 0)

    Change in PT during at least 76 weeks from treatment onset (week 0) is presented. The data is presented per the last dose level which the participants have reached at the time of assessment.

  16. Change in Activated Partial Thromboplastin Time (APTT) During 24 Weeks From Treatment Onset

    Time frame: During 24 weeks from treatment onset (week 0)

    Change in APTT during 24 weeks from treatment onset (week 0) is presented. The data is presented per the last dose level which the participants have reached at the time of assessment.

  17. Change in Activated Partial Thromboplastin Time (APTT) During at Least 76 Weeks From Treatment Onset

    Time frame: During at least 76 weeks from treatment onset (week 0)

    Change in APTT during at least 76 weeks from treatment onset (week 0) is presented. The data is presented per the last dose level which the participants have reached at the time of assessment.

  18. Change in Anti-thrombin (AT) During 24 Weeks From Treatment Onset

    Time frame: During 24 weeks from treatment onset (week 0)

    Change in AT during 24 weeks from treatment onset (week 0) is presented. The data is presented per the last dose level which the participants have reached at the time of assessment.

  19. Change in Anti-thrombin (AT) After at Least 76 Weeks From Treatment

    Time frame: During at least 76 weeks from treatment onset (week 0)

    Change in AT after at least 76 weeks from treatment onset (week 0) is presented. The data is presented per the last dose level which the participants have reached at the time of assessment.

  20. Concentration of Concizumab Prior to the Last Dose Administration at 24 Weeks

    Time frame: Prior to the last dose administration at 24 weeks

    Concentration of concizumab prior to the last dose administration at 24 weeks is presented. The data is presented per the last dose level which the participants have reached at the time of assessment.

  21. Concentration of Concizumab Prior to the Last Dose Administration After at Least 76 Weeks

    Time frame: Prior to the last dose administration after at least 76 weeks

    Concentration of concizumab prior to the last dose administration after at least 76 weeks is presented. The data is presented per the last dose level which the participants have reached at the time of assessment.

  22. Free Tissue Factor Pathway Inhibitor (TFPI) Concentration Value Prior to the Last Dose Administration at 24 Weeks

    Time frame: Prior to the last dose administration at 24 weeks

    Free TFPI (TFPI not bound to concizumab) concentration value prior to the last dose administration at 24 weeks is presented. The data is presented per the last dose level which the participants have reached at the time of assessment.

  23. Free Tissue Factor Pathway Inhibitor (TFPI) Concentration Value Prior to the Last Dose Administration After at Least 76 Weeks

    Time frame: Prior to the last dose administration after at least 76 weeks

    Free TFPI concentration value prior to the last dose administration after at least 76 weeks is presented. The data is presented per the last dose level which the participants have reached at the time of assessment.

  24. Peak Thrombin Generation Prior to the Last Dose Administration at 24 Weeks

    Time frame: Prior to the last dose administration at 24 weeks

    Peak thrombin generation is the maximal concentration of thrombin formed at a given point in time. Peak thrombin generation prior to the last dose administration at 24 weeks is presented. The data is presented per the last dose level which the participants have reached at the time of assessment.

  25. Peak Thrombin Generation Prior to the Last Dose Administration After at Least 76 Weeks

    Time frame: Prior to the last dose administration after at least 76 weeks

    Peak thrombin generation is the maximal concentration of thrombin formed at a given point in time. Peak thrombin generation prior to the last dose administration after at least 76 weeks is presented. The data is presented per the last dose level which the participants have reached at the time of assessment.

  26. Endogenous Thrombin Potential Prior to the Last Dose Administration at 24 Weeks

    Time frame: Prior to the last dose administration at 24 weeks

    The endogenous thrombin potential (ETP), defined as the amount of thrombin which can be generated after the in vitro activation of coagulation with tissue factor as trigger and phospholipids as platelet substitute. Endogenous thrombin potential prior to the last dose administration at 24 weeks is presented. The data is presented per the last dose level which the participants have reached at the time of assessment.

  27. Endogenous Thrombin Potential Prior to the Last Dose Administration After at Least 76 Weeks

    Time frame: Prior to the last dose administration after at least 76 weeks

    The endogenous thrombin potential (ETP), defined as the amount of thrombin which can be generated after the in vitro activation of coagulation with tissue factor as trigger and phospholipids as platelet substitute. Endogenous thrombin potential prior to the last dose administration after at least 76 weeks is presented. The data is presented per the last dose level which the participants have reached at the time of assessment.

  28. Thrombin Generation Velocity Index Prior to the Last Dose Administration at 24 Weeks

    Time frame: Prior to the last dose administration at 24 weeks

    Thrombin generation velocity index represents the effective rate of thrombin generation between lag time and time to peak. Thrombin generation velocity index prior to the last dose administration at 24 weeks is presented. The data is presented per the last dose level which the participants have reached at the time of assessment.

  29. Thrombin Generation Velocity Index Prior to the Last Dose Administration After at Least 76 Weeks

    Time frame: Prior to the last dose administration after at least 76 weeks

    Thrombin generation velocity index represents the effective rate of thrombin generation between lag time and time to peak. Thrombin generation velocity index prior to the last dose administration after at least 76 weeks is presented. The data is presented per the last dose level which the participants have reached at the time of assessment.

Sponsors and collaborators

Lead sponsor

Novo Nordisk A/S

Industry

Registry information

Official study title

A Multi-Centre Trial Evaluating Efficacy and Safety of Prophylactic Administration of Concizumab in Patients With Severe Haemophilia A Without Inhibitors

Acronym: explorer™5

Important dates

Study start
2017
Primary completion
2018
Study completion
2020
First posted
Jun 22, 2017
Registry last updated
Nov 16, 2021

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.